Payment overview · 2025
General Payments
$79.71
3 reported records · 2 companies
Healthcare provider profile · identity verified
Domingo Yang, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CLIFTON, NJ · NPI 1518286939
Verified facts
What the public records show
CMS Open Payments records show Domingo Yang, M.D. received $79.71 in general payments during 2025 across 3 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 58.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Brilinta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $46.66 | 58.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.05 | 41.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $79.71 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $46.66 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 665 | 93 |
| Divalproex Sodium | Divalproex Sodium | 511 | 62 |
| Lisinopril | Lisinopril | 395 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 366 | 63 |
| Metformin Hcl | Metformin Hcl | 329 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 285 | 47 |
| Mirtazapine | Mirtazapine | 260 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 258 | 32 |
| Donepezil Hcl | Donepezil Hcl | 198 | 28 |
| Eliquis | Apixaban | 196 | 27 |
| Gabapentin | Gabapentin | 185 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 185 | 28 |
| Sertraline Hcl | Sertraline Hcl | 177 | 20 |
| Trazodone Hcl | Trazodone Hcl | 176 | 26 |
| Benztropine Mesylate | Benztropine Mesylate | 153 | 22 |
| Risperidone | Risperidone | 152 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 150 | 22 |
| Levetiracetam | Levetiracetam | 144 | 19 |
| Olanzapine | Olanzapine | 127 | 22 |
| Buspirone Hcl | Buspirone Hcl | 122 | 24 |
| Baclofen | Baclofen | 121 | suppressed |
| Latanoprost | Latanoprost | 110 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 105 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 103 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 100 | 24 |
| Glipizide | Glipizide | 99 | 16 |
| Amlodipine Besylate | Amlodipine Besylate | 98 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 18 |
| Lactulose | Lactulose | 97 | 11 |
| Januvia | Sitagliptin Phosphate | 93 | 15 |
| Finasteride | Finasteride | 89 | suppressed |
| Losartan Potassium | Losartan Potassium | 87 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 14 |
| Haloperidol | Haloperidol | 82 | suppressed |
| Memantine Hcl | Memantine Hcl | 82 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 82 | 19 |
| Carbamazepine | Carbamazepine | 70 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 68 | 12 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 66 | suppressed |
| Budesonide | Budesonide | 64 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 64 | 13 |
| Memantine Hcl Er | Memantine Hcl | 61 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 60 | suppressed |
| Furosemide | Furosemide | 57 | 18 |
| Sevelamer Carbonate | Sevelamer Carbonate | 54 | suppressed |
| Brilinta | Ticagrelor | 50 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 50 | suppressed |
| Simvastatin | Simvastatin | 48 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 44 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 44 | 25 |
| Aripiprazole | Aripiprazole | 41 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 40 | 15 |
| Levemir | Insulin Detemir | 39 | suppressed |
| Famotidine | Famotidine | 37 | suppressed |
| Ibuprofen | Ibuprofen | 37 | suppressed |
| Lamotrigine | Lamotrigine | 35 | suppressed |
| Nystatin | Nystatin | 35 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 34 | suppressed |
| Lorazepam | Lorazepam | 34 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 33 | 12 |
| Carbamazepine Er | Carbamazepine | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | 12 |
| Clonazepam | Clonazepam | 29 | suppressed |
| Insulin Lispro | Insulin Lispro | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 13 |
| Torsemide | Torsemide | 28 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Lacosamide | Lacosamide | 24 | suppressed |
| Potassium Chloride | Potassium Chloride | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 23 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Olanzapine Odt | Olanzapine | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 13 |
| Silodosin | Silodosin | 22 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Allopurinol | Allopurinol | 20 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Alogliptin | Alogliptin Benzoate | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 19 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 18 | suppressed |
| Omeprazole | Omeprazole | 18 | suppressed |
| Acetylcysteine | Acetylcysteine | 17 | suppressed |
| Austedo | Deutetrabenazine | 17 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | suppressed |
| Rhopressa | Netarsudil Mesylate | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 13 | suppressed |
| Darunavir | Darunavir | 13 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 11 |
| Pregabalin | Pregabalin | 13 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 13 | suppressed |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Aristada | Aripiprazole Lauroxil | 12 | suppressed |
| Carvedilol | Carvedilol | 12 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Tolvaptan | Tolvaptan | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Clozapine | Clozapine | 11 | suppressed |
| Enulose | Lactulose | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $79.71 · 3 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, Kerendia | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error